Tosteson Anna N A, Stout Natasha K, Fryback Dennis G, Acharyya Suddhasatta, Herman Benjamin A, Hannah Lucy G, Pisano Etta D
The Dartmouth Institute for Health Policy and Clinical Practice, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA.
Ann Intern Med. 2008 Jan 1;148(1):1-10. doi: 10.7326/0003-4819-148-1-200801010-00002.
The DMIST (Digital Mammography Imaging Screening Trial) reported improved breast cancer detection with digital mammography compared with film mammography in selected population subgroups, but it did not assess the economic value of digital relative to film mammography screening.
To evaluate the cost-effectiveness of digital mammography screening for breast cancer.
Validated, discrete-event simulation model.
Data from DMIST and publicly available U.S. data.
U.S. women age 40 years or older.
Lifetime.
Societal and Medicare.
All-film mammography screening; all-digital mammography screening; and targeted digital mammography screening, which is age-targeted digital mammography (for women <50 years of age) and age- and density-targeted digital mammography (for women <50 years of age or women > or =50 years of age with dense breasts).
Cost per quality-adjusted life-year (QALY) gained.
RESULTS OF BASE-CASE ANALYSIS: All-digital mammography screening cost $331,000 (95% CI, $268,000 to $403,000) per QALY gained relative to all-film mammography screening but was more costly and less effective than targeted digital mammography screening. Targeted digital mammography screening resulted in more screen-detected cases of cancer and fewer deaths from cancer than either all-film or all-digital mammography screening, with cost-effectiveness estimates ranging from $26,500 (CI, $21,000 to $33,000) per QALY gained for age-targeted digital mammography to $84,500 (CI, $75,000 to $93,000) per QALY gained for age- and density-targeted digital mammography. In the Medicare population, the cost-effectiveness of density-targeted digital mammography screening varied from a base-case estimate of $97,000 (CI, $77,000 to $131,000) to $257,000 per QALY gained (CI, $91,000 to $536,000) in the alternative-case analyses, in which the sensitivity of film mammography was increased and the sensitivity of digital mammography in women with nondense breasts was decreased.
Results were sensitive to the cost of digital mammography and to the prevalence of dense breasts.
Results were dependent on model assumptions and DMIST findings.
Relative to film mammography, screening for breast cancer by using all-digital mammography is not cost-effective. Age-targeted screening with digital mammography seems cost-effective, whereas density-targeted screening strategies are more costly and of uncertain value, particularly among women age 65 years or older.
数字乳腺断层合成影像筛查试验(DMIST)报告称,在特定人群亚组中,与传统乳腺钼靶摄影相比,数字乳腺断层合成影像能提高乳腺癌检测率,但未评估数字乳腺断层合成影像相对于传统乳腺钼靶摄影筛查的经济价值。
评估数字乳腺断层合成影像筛查乳腺癌的成本效益。
经过验证的离散事件模拟模型。
DMIST的数据和美国公开可用的数据。
40岁及以上的美国女性。
终生。
社会和医疗保险。
全传统乳腺钼靶摄影筛查;全数字乳腺断层合成影像筛查;以及针对性数字乳腺断层合成影像筛查,即年龄针对性数字乳腺断层合成影像(针对年龄小于50岁的女性)和年龄及密度针对性数字乳腺断层合成影像(针对年龄小于50岁或年龄大于或等于50岁且乳腺致密的女性)。
每获得一个质量调整生命年(QALY)的成本。
相对于全传统乳腺钼靶摄影筛查,全数字乳腺断层合成影像筛查每获得一个QALY的成本为33.1万美元(95%CI,26.8万美元至40.3万美元),但比针对性数字乳腺断层合成影像筛查成本更高且效果更差。与全传统或全数字乳腺断层合成影像筛查相比,针对性数字乳腺断层合成影像筛查能检测出更多的癌症病例且癌症死亡人数更少,成本效益估计范围为年龄针对性数字乳腺断层合成影像每获得一个QALY的成本为2.65万美元(CI,2.1万美元至3.3万美元),年龄及密度针对性数字乳腺断层合成影像每获得一个QALY的成本为8.45万美元(CI,7.5万美元至9.3万美元)。在医疗保险人群中,密度针对性数字乳腺断层合成影像筛查的成本效益在基础病例估计为9.7万美元(CI,7.7万美元至13.1万美元)至替代病例分析中每获得一个QALY的成本为25.7万美元(CI,9.1万美元至53.6万美元)之间变化,在替代病例分析中,传统乳腺钼靶摄影的敏感性增加,而非致密乳腺女性中数字乳腺断层合成影像的敏感性降低。
结果对数字乳腺断层合成影像的成本和致密乳腺的患病率敏感。
结果依赖于模型假设和DMIST的研究结果。
相对于传统乳腺钼靶摄影,使用全数字乳腺断层合成影像进行乳腺癌筛查不具有成本效益。年龄针对性的数字乳腺断层合成影像筛查似乎具有成本效益,而密度针对性的筛查策略成本更高且价值不确定,尤其是在65岁及以上的女性中。